A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
Latest Information Update: 14 Apr 2020
At a glance
- Drugs PHP 303 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors pH Pharma
Most Recent Events
- 09 Apr 2020 Status changed from recruiting to completed.
- 11 Mar 2019 Status changed from not yet recruiting to recruiting.
- 19 Dec 2018 New trial record